Cleveland, Ohio 44195


RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme.

Study summary:

OBJECTIVES: - Determine the response rate of patients with recurrent or progressive glioblastoma multiforme treated with erlotinib. - Determine the progression-free and overall survival of patients treated with this drug. OUTLINE: Patients receive oral erlotinib daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for survival. PROJECTED ACCRUAL: A total of 73 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically confirmed glioblastoma multiforme - Radiographic evidence of recurrence or progression - Biopsies to confirm tumor recurrence allowed if a sufficent percentage of cases are confirmed to be recurrent tumor - Previously treated with optimal radiotherapy and at least 1 cytotoxic chemotherapy regimen PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Not specified Life expectancy - Not specified Hematopoietic - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic - Bilirubin no greater than 2 times normal - Alkaline phosphatase no greater than 2 times normal - ALT no greater than 3 times normal Renal - BUN no greater than 1.5 times normal OR - Creatinine no greater than 1.5 times normal Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No medical condition that would interfere with oral administration of erlotinib - No other medical or psychiatric illness that would preclude study therapy - No active infection - No other malignancy within the past 3 years except surgically cured carcinoma in situ of the cervix or nonmelanoma skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent immunotherapy for brain cancer - No concurrent biologic therapy for brain cancer Chemotherapy - See Disease Characteristics - At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered - No concurrent chemotherapy for brain cancer Endocrine therapy - Concurrent glucocorticosteroids allowed - No concurrent hormonal therapy for brain cancer Radiotherapy - See Disease Characteristics Surgery - Not specified Other - No prior epidermal growth factor receptor (EGFR) inhibitor - No concurrent EGFR inhibitor - No other concurrent antineoplastic therapy - No concurrent anti-epileptic agents other than modest- or non-enzyme-inducing drugs such as the following: - Gabapentin - Lamotrigine - Divalproex - Felbamate - Levetiracetam - Tiagabine - Topiramate - Zonisamide



Primary Contact:

Study Chair
Michael A. Vogelbaum, MD, PhD
The Cleveland Clinic

Backup Contact:


Location Contact:

Cleveland, Ohio 44195
United States

Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente
Phone: 866-223-8100

Site Status: Recruiting

Data Source:

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.